Analysis of Pemphigoid Linked to Quinolone Antibiotics: Insights from FDA Adverse Event Reports and Literature Review
By
Hai-Hong Lin
Kai-Li Mao
Liu-Cheng Li
Huan-Hao Zhou
July 17, 2026
Clinical Scorecard: Analysis of Pemphigoid Linked to Quinolone Antibiotics: Insights from FDA Adverse Event Reports and Literature Review
At a Glance
Category Detail
Condition Pemphigoid Key Mechanisms Association with quinolone antibiotics, particularly ofloxacin, levofloxacin, and ciprofloxacin. Target Population Elderly females receiving quinolone therapy. Care Setting Pharmacovigilance analysis using FDA Adverse Event Reporting System (FAERS).
Key Highlights
Significant disproportionality signals for specific quinolone antibiotics. Most adverse events reported within 30 days of quinolone therapy. Study highlights methodological limitations in establishing causality. Emphasizes the need for sensitivity analyses to validate findings. Calls for the inclusion of clinical pharmacists in pharmacovigilance. Guideline-Based Recommendations
Diagnosis
Consider potential drug-induced pemphigoid in patients receiving quinolone antibiotics. Management
Monitor for signs of pemphigoid in patients treated with quinolone antibiotics. Monitoring & Follow-up
Early monitoring during quinolone therapy is advised due to reported adverse events. Risks
Polypharmacy may confound the association between quinolone use and pemphigoid. Patient & Prescribing Data
Elderly patients, particularly females, on quinolone antibiotics.
Adverse events may be influenced by concomitant medications and underlying infections.
Clinical Best Practices
Incorporate clinical pharmacists in monitoring and reporting adverse drug reactions. Follow established guidelines for pharmacovigilance disproportionality analysis. Conduct independent cohort studies for validation of adverse event signals. Related Resources & Content
